Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428310 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
A Phase 1 study, sponsored by Rock Creek Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 109
- Enrollment target
NCT01428310: Completed Phase 1 study, sponsored by Rock Creek Pharmaceuticals.
NCT01428310 is a Phase 1 study that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 109 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01428310, a Phase 1 study, has completed, sponsored by Rock Creek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study product and visit the study site for assessment of desire to smoke and collection of samples for the evaluation of smoking-related biomarkers.
Primary Outcome
craving is assessed by changes in questionnaire answers over time
Interventions
- DIETARY_SUPPLEMENT Anatabloc(TM)
- DIETARY_SUPPLEMENT CigRx(R)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2011-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01428310 record still lists
NCT01428310 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% higher).
The record links to 0 conditions, and to 2 interventions - of which Anatabloc(TM) is the first listed.
NCT01428310 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01428310 about?
NCT01428310 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke". This study will consist of 2 phases. Phase 1 will be a one day crossover study to see the effects of study product on a smoker's desire to smoke, measured by changes in scores on questionnaires given over time. Phase 2 will be a two-week extension, in which subjects will self-administer the study pr...
What is the current status of trial NCT01428310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2011-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01428310?
The interventions under investigation include: Anatabloc(TM) (DIETARY_SUPPLEMENT), CigRx(R) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01428310?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01428310's enrollment target sits among peer trials
109 522nd of 2000 higher than 1,478 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia